01
Multi-Peptide Complex
Multi-Peptide Complex
Core of repair and anti-aging — awakening the cell's rhythm of self-renewal.
VI. BUSINESS MODEL
Dual‑Engine Drive
Perpetual Force
Dual Engines · Perpetual Renewal.
There are two well-trodden paths in corporate strategy: technology-driven and capital-driven. We chose a third — biotechnology drives product research and development; capital advances the business as a whole. Two engines turning one another, forming a self-iterating closed loop.
VI-1 INDUSTRY INSIGHT
Why the women's wellness market must be rebuilt
Why the women's wellness market must be rebuilt.
For the past century, women's beauty has been depicted again and again — but never truly studied.
The global women's wellness market reached approximately USD 50 billion in 2024, with a forecast compound annual growth rate exceeding 9%. Yet of this, the share genuinely allocated to research in "inner beauty" and "intimate health" is less than one-tenth of that devoted to topical skincare.
The market lacks neither capital nor demand — what is missing is the mechanism to bind capital to long-cycle research. A single essence in intimate care requires 7 to 10 years from molecular design to clinical validation, while the patience of conventional beauty capital rarely exceeds 18 months.
Toyo Bijin exists so that the most patient research may meet the most enduring capital.
~$50B
Global women's wellness market, 2024 USD
Allied Market Research
9.4%
Global women's wellness CAGR, 2024-2030
<10%
R&D investment share in intimate care
01
VI-2 ENGINE 01
Every product developed at the frontier of biotechnology
Every product, engineered at the molecular frontier.
All our products are developed with the most advanced biotechnology. The Kyoto Life Sciences Institute (founded in 2014) is the physical anchor of this capability — the source from which the Group moves from raw material to molecule, and from molecule to formulation.
The institute is overseen by an international scientific advisory board, including dermatology professors from Harvard Medical School and life sciences academicians from Kyoto University, ensuring that every R&D decision is subject to independent academic scrutiny.
Proprietary patents: 80+. Clinical-stage research projects: 12. The 12th-generation revitalizing complex entered the flagship line in spring 2026, with the next generation of molecular design already in parallel development.
CORE TECHNOLOGIES
The core biotechnologies we command
A breadth of disciplines, integrated into one formulation language.
02
Ceramide Architecture
Ceramide Architecture
Rebuilding the skin barrier, with long-lasting moisture retention and luminosity.
03
Nano Hyaluronic Acid
Nano Hyaluronic Acid
A dual-delivery system that hydrates the deep layer and seals the surface in parallel.
04
Stem Cell Culture
Stem Cell Culture
The principles of regenerative medicine applied to dermal repair and firming.
05
Microbiome Science
Microbiome Science
Restoring microbial balance across the skin and intimate ecosystem.
06
Epigenetic Modulation
Epigenetic Modulation
The frontier of cellular activation, awakening the expression of youth genes.
07
Sustained Release & Encapsulation
Sustained Release & Encapsulation
Formulation engineering for the stable, controlled release of active ingredients.
02
VI-3 ENGINE 02
Capital that advances the business as a whole
Capital that compounds with capability.
Toyo Bijin Capital is the Group's strategic investment arm. The role of capital is to advance the Group's business as a whole — not to exist as an independent financial portfolio.
We do not invest in financial portfolios. We invest only where there is industrial synergy with one of the Group's three axes — research, raw materials, or distribution: upstream biotech startups, mid-stream manufacturing-process patents, and downstream premium channels.
To date, the strategic portfolio comprises 8 companies, with the results of 3 already flowing back into the Group's own product lines. By 2027, the portfolio is planned to expand to 12.
PORTFOLIO AT A GLANCE
32.4%
Strategic portfolio annualized IRR
$2.45B
Current holdings valuation (USD)
8 → 12
Portfolio companies (2027 target)
8.5 yrs
Average strategic holding period
VI-4 SYNERGY
How the two engines turn one another
How the two engines turn one another.
One example is enough to show how the loop turns.
PHASE 01
Strategic Investment
The Group's strategic arm once invested in a scientist devoted to signal-peptide research, securing for the Group an advanced solution in "multi-peptide formulation."
PHASE 02
Research Translation
The Kyoto Institute used the formulation as the basis for molecular design, formulation harmonization, and clinical validation — turning it into the core ingredient of the next-generation product.
PHASE 03
Product Launch
The formulation entered the flagship line, where its dual validity — scientific depth and commercial value — was confirmed in the Group's core markets.
PHASE 04
Return to Capital
The returns of success flow back into the strategic investment fund. A new round of research and investment begins from here.
Investment grants research more patience; research grants investment deeper conviction. This is the essence of the closed loop: biotechnology drives product R&D, and capital advances the business as a whole.
VI-5 NEXT DECADE
Toward the next century
The path continues.
30
By 2030 · Global markets
Expanding Group brands to 30 countries worldwide, with focused presence across the Asia-Pacific, North America, and Europe.
13th
2028 · 13th-generation revitalizing complex
The next-generation core proprietary ingredient completes full clinical validation, expected to drive the next evolution of the Bijin Privé line.
12
2027 · Strategic portfolio expansion
Toyo Bijin Capital expands its strategic portfolio to 12 industrially synergistic holdings.
8%+
Ongoing · R&D investment as % of net sales
R&D investment sustained above 8% of net sales — well beyond the industry average of 2-3%.